Evidence map›Paper›PMID 32164664›Full record

ArticleBMC biotechnology2020

Optimised production of an anti-fungal antibody in Solanaceae hairy roots to develop new formulations against Candida albicans.

Marcello Catellani, Chiara Lico, Mauro Cerasi, Silvia Massa, Carla Bromuro, Antonella Torosantucci, Eugenio Benvenuto, Cristina Capodicasa

Open access · goldAbstract read
In one paragraph

Article in BMC biotechnology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.3field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. The Pathogenesis ofPolish journal of microbiology · 2021
    Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Marcello CatellaniDepartment of Sustainability, Laboratory Biotechnologies, ENEA, Casaccia Research Center, Via Anguillarese 301, 00123, Rome, Italy.
Chiara LicoDepartment of Sustainability, Laboratory Biotechnologies, ENEA, Casaccia Research Center, Via Anguillarese 301, 00123, Rome, Italy.
Mauro CerasiDepartment of Sustainability, Laboratory Biotechnologies, ENEA, Casaccia Research Center, Via Anguillarese 301, 00123, Rome, Italy.
Silvia MassaDepartment of Sustainability, Laboratory Biotechnologies, ENEA, Casaccia Research Center, Via Anguillarese 301, 00123, Rome, Italy.
Carla BromuroDepartment of Infectious, Parasitic and Immune-Mediated Diseases, Istituto Superiore di Sanità, Rome, Italy.
Antonella TorosantucciDepartment of Infectious, Parasitic and Immune-Mediated Diseases, Istituto Superiore di Sanità, Rome, Italy.
Eugenio BenvenutoDepartment of Sustainability, Laboratory Biotechnologies, ENEA, Casaccia Research Center, Via Anguillarese 301, 00123, Rome, Italy.
Cristina CapodicasaDepartment of Sustainability, Laboratory Biotechnologies, ENEA, Casaccia Research Center, Via Anguillarese 301, 00123, Rome, Italy. cristina.capodicasa@enea.it.
National Agency for New Technologies, Energy and Sustainable Economic Development · ITENEA Casaccia Research CentreIstituto Superiore di Sanità · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundInfections caused by fungi are often refractory to conventional therapies and urgently require the development of novel options, such as immunotherapy. To produce therapeutic antibodies, a plant-based expression platform is an attractive biotechnological strategy compared to mammalian cell cultures. In addition to whole plants, hairy roots (HR) cultures can be used, representing an expression system easy to build up, with indefinite growth while handled under containment conditions.

resultsIn this study the production in HR of a recombinant antibody, proved to be a good candidate for human immunotherapy against fungal infections, is reported. Expression and secretion of this antibody, in an engineered single chain (scFvFc) format, by HR from Nicotiana benthamiana and Solanum lycopersicum have been evaluated with the aim of directly using the deriving extract or culture medium against pathogenic fungi. Although both Solanaceae HR showed good expression levels (up to 68 mg/kg), an optimization of rhizosecretion was only obtained for N. benthamiana HR. A preliminary assessment to explain this result highlighted the fact that not only the presence of proteases, but also the chemical characteristics of the growth medium, can influence antibody yield, with implications on recombinant protein production in HR. Finally, the antifungal activity of scFvFc 2G8 antibody produced in N. benthamiana HR was evaluated in Candida albicans growth inhibition assays, evidencing encouraging results.

conclusionsProduction of this anti-fungal antibody in HR of N. benthamiana and S. lycopersicum elucidated factors affecting pharming in this system and allowed to obtain promising ready-to-use immunotherapeutics against C. albicans.

Indexed as

Antifungal AgentsCandida albicansHomologous RecombinationNicotianaPlant RootsPlants, Genetically ModifiedProtein EngineeringRecombinant ProteinsSingle-Chain AntibodiesSolanaceaeSolanum lycopersicumAntifungal AgentsRecombinant ProteinsSingle-Chain AntibodiesFungal infectionsHairy rootsMolecular farmingProteolytic activityRecombinant antibodyRhizosecretion

Identifiers

PMID32164664
PMCPMC7069033
OpenAlexW3012216319

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.